Daily broccoli microgreens for breast cancer survivors with obesity
Official title: Metabotyping of a Functional Food, Broccoli Microgreen, in Obese Breast Cancer Survivors
Run by University of Maryland, Baltimore · NCT07032545 · Data updated 2026-11-12
This two-week test will see if eating one cup of fresh broccoli microgreens each day is doable and changes metabolism and gut health in obese breast cancer survivors.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | Women only |
| Enrollment | 24 (estimated) |
| Sponsor | University of Maryland, Baltimore Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | December 3, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | December 23, 2025 |
| Trial ID | NCT07032545 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women with stage I–III breast cancer who are 2–60 months after curative treatment and have a BMI over 30 kg/m², who can avoid other cruciferous vegetables and consent to sample collection, are ideal candidates.
✕Probably not a fit
People with gastrointestinal contraindications, allergy or intolerance to cruciferous vegetables, pregnancy or breastfeeding, recent eating-disorder history, or those already taking broccoli supplements are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-arm, two-week pilot intervention enrolling 24 obese (BMI >30) women who are 2–60 months post-curative treatment for stage I–III breast cancer at the University of Maryland, Baltimore. Participants will consume one serving (~57 g, one cup) of fresh broccoli microgreens daily and avoid other cruciferous vegetables during the intervention. Blood and fecal samples plus questionnaires will be collected at baseline and after two weeks to measure compliance, body composition, glucose and lipid markers, inflammatory markers, and gut microbiome/metabolite changes. The primary aim is to test feasibility and adherence, with secondary exploratory endpoints examining short-term metabolic and gut-health responses to the intervention.
Why it matters
Potential benefit: If successful, adding broccoli microgreens to the diet could modestly improve metabolic markers and gut health and potentially reduce obesity-related risks for cancer recurrence.
How similar studies have gone: Animal studies have shown beneficial effects of broccoli microgreens on gut health and metabolism, but human data are limited and this is an early proof-of-concept in people.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female * Had a diagnosis of breast cancer (Stage I-III) * 2 to 60 months post-curative treatment (surgery, chemotherapy, and/or radiation) * BMI \> 30 kg/m² (obese classification) * Willing to avoid cruciferous vegetables during the study * Able to sign an IRB-approved consent form Exclusion Criteria: * Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., GI conditions, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder). * Allergy or intolerance to cruciferous vegetables * Currently taking broccoli extract supplements
Where it's running
-
Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Yuanyuan (Rose) Li, M.D., Ph.D. — University of Maryland
- Study coordinator: Yuanyuan (Rose) Li, M.D., Ph.D.
- Email: roseli15@umd.edu
- Phone: 13014050776
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
IBI3046 in Overweight or Obesity
This study tests how safe and tolerable IBI3046 is in adults with overweight or obesity in China.
-
Weight management program for breast cancer survivors in rural communities
This program will test whether a 12-week remote WeCan-Rural program helps rural breast cancer survivors with obesity lose weight, ease symptoms, and lower heart disease risk.
-
Sleep behavioral program for adolescents with overweight or obesity
This trial will test whether adding a sleep-focused behavioral program to usual weight treatment helps teens (13–17) with overweight or obesity who have poor sleep improve body composition and health markers.
-
Robotic versus laparoscopic conversion to RYGB for revision bariatric surgery
We will see if robotic surgery or laparoscopy leads to fewer postoperative complications for people having revision bariatric surgery converted to RYGB.
-
Bone health, vitamin D, weight, and fractures in children
See if blood markers (alkaline phosphatase, calcium, PTH, vitamin D), body weight, and calcium intake are linked to fractures in children aged 3–15 after low-energy trauma.
-
Efsubaglutide alfa for adults with overweight or obesity (SPARKLE)
This trial will test whether efsubaglutide alfa injections given weekly or every few weeks help adults with overweight or obesity lose weight safely.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.